Dear friends,
please read the news
40-45 per cent news in Pakistan are spurious.
What does this news mean to drug
resistance, anti-TB treatment, Anti-Retroviral Therapy, and other
essential medicines? Please be welcome to share your perspectives,
experiences and comments. A Stop-TB eForum member Ayyaz Kiani from Pakistan has commented on this news as below:
[BEGIN]
"...THERE REMAINS A SIGNIFICANT PROBABILITY THAT SOME PATIENTS WOULD GET SPURIOUS ANTI-TB MEDICINES CAUSING TREATMENT FAILURES AND DRUG RESISTANCE"
Dear Stop-TB members,
Availability of spurious medicines in Pakistan market is indeed a problem and we have been campaigning against it for a number of years.
It is quite likely that such malpractices by the industry might also prevail in the anti-TB medicines market as well. However empirical research on the subject has been conspicuously missing.
It is also well known that the government machinery for surveillance and quality assurance is deficient in qualitative as well as quantitative terms.
However the issue of quality of medicines is a complicated one and depends on a number of additional factors like the process of licensing and registration of the manufacturing companies and their products, overall number of products in the market, cross border smuggling and the overall legal and policy framework in the country.
Stories of corruption and negligence in pharmaceutical sector are rampant and lead to low confidence in patients and healthcare providers alike. As a result there has been a trend of prescribing brands of multinational companies (as they are generally believed to be less likely to be spurious) which practice come at a high premium and become a heavy burden to the public exchequer and the shallow pockets of the consumers.
The anti-TB program in the country has been cognizant of these issues and is taking extra care for quality assurance in the medicines procured directly by them. Nevertheless there remains a significant probability that some patients would get spurious anti-TB medicines causing treatment failures and drug resistance.
It is high time that research is carried out to quantify the problem and corrective measures are taken to rule out malpractices and bad patient outcomes.
Ayyaz Kiani
Consultant, Access to Medicines
Islamabad, Pakistan
Email: ayyaz_kiani@hotmail.com
[END]